Asset Details
Do you wish to reserve the book?
Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats
Do you wish to request the book?
Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Therapeutic effects of mesenchymal stem cell-derived microvesicles on pulmonary arterial hypertension in rats
2014
Overview
Aim： Microvesicles （MVs） are nanoscale membrane fragments released from virtually all cell types upon activation or apoptosis, and may contribute to the beneficial effects of stem cell therapy. In this study, we investigated the therapeutic effects of mesenchymal stem cell （MSC） derived MVs （MSC-MVs） on pulmonary artery hypertension （PAH） in rats. Methods： MSC-MVs were isolated from rat bone marrow MSCs that were cultured in a serum-free conditioned medium. Transmission electron microscopy （TEM）, flow cytometry and nanoparticle tracking analysis （NTA） were used to characterize the MVs. Adult SD rats were injected with monocrotaline （50 mg/kg, sc） to induce PAH. Three weeks later, the rats were intravenously injected with MSCs, MSC-MVs or saline for 2 weeks. At the end of treatments, the hemodynamic parameters and pathological right ventricular and pulmonary arterial remodeling were analyzed in each group. Results： The MSC-MVs showed general morphologic characteristics of MVs and expressed annexin V and CD29 markers under TEM, and their size ranged from 40 to 300 nm. Intravenous injection of MSC-MVs or MSCs significantly ameliorated the mean pulmonary artery pressure （mPAP） and mean right ventricle pressure （mRVP） in PAH rats. Furthermore, intravenous injection of MSC-MVs or MSCs significantly decreased the right ventricle （RV） hypertrophy and pulmonary arteriole area index （AI） and thickness index （TI） in PAH rats. Conclusion： Intravenous injection of MSC-MVs or MSCs produces similar beneficial effects for treating PAH, and our results provide a basis for cell-free approach in stem cell therapy.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Biomedical and Life Sciences
/ Cell-Derived Microparticles - physiology
/ Heart Ventricles - physiopathology
/ Hypertension, Pulmonary - physiopathology
/ Hypertension, Pulmonary - therapy
/ Mesenchymal Stromal Cells - physiology
/ Original
/ Pulmonary Artery - physiology
/ Rats
/ SD大鼠
/ Vaccine
/ 微泡
/ 条件培养基
/ 治疗效果
/ 肺动脉高压
/ 透射电子显微镜
/ 间充质干细胞
/ 静脉注射
